Invivyd Downgraded to Hold by D. Boral Capital: A Shift in Analyst Perspectives

Invivyd (IVVD) has been downgraded to Hold by D. Boral Capital from a previous Buy rating. The analyst, Jason Kolbert, did not provide a current price target or percentage change in target. Recently, there have been multiple Buy ratings and price target increases, including a 100% increase to $10.00 from HC Wainwright & Co. Invivyd is a clinical-stage biopharmaceutical company focused on developing antibody-based solutions for infectious diseases. The average target price for Invivyd is $7.33, implying an upside of 205.56% from the current price of $2.40.